Omniscient Neurotechnology Appoints Two New Members to Its Board of Directors
October 24 2022 - 8:30AM
Omniscient Neurotechnology, the brain mapping company creating new
possibilities in brain health, today announced the appointment of
Barbara Nelson and Surbhi Sarna to its board of directors.
Both appointees are visionaries across the biotech, healthcare
and technology industries and bring a unique perspective to the
company’s corporate strategy and growth. They, along with the
existing board members, will strategically guide Omniscient as it
develops products that unlock new insights into advanced brain
care.
“Omniscient is a global leader in connectomics, but we have much
work ahead of us to scale to our full potential,” said Chairman
Daniel Appleby. “Barbara and Surbhi’s experience in guiding
cutting-edge technology companies from startup to Nasdaq will be
invaluable as we grow in the US and around the world.”
“Barbara and Surbhi both add tremendous value to our board of
directors. I look forward to working with them and am confident
that their deep industry expertise will be invaluable as we usher
humankind into a new era of precision brain medicine,” said
Omniscient CEO Stephen Scheeler.
Omniscient is the first company to develop technology to
translate connectomic research for actionable use by clinicians and
surgeons. It does so via its product, Quicktome, which is an
FDA-cleared precision brain mapping platform that today allows
neurosurgeons to visualize a patient’s unique brain networks prior
to critical surgery.
About the new appointees
Barbara Nelson is a C-level technology
executive with over 15 years of General Management and Profit &
Loss leadership, across markets including SaaS, IaaS,
cybersecurity, data management, mobile and consumer electronics.
She has led global P&Ls, twice as CEO, for companies ranging
from VC funded startups to Fortune 500 leaders such as Quantum and
Intel; most recently having led strategy for the $3 billion
consumer business at Western Digital. Barbara also currently serves
as independent director on the boards of GSI Technology (Nasdaq:
GSIT) and Backblaze (Nasdaq: BLZE), a business she led through a
successful IPO.
Surbhi Sarna is the founder and former CEO of
nVision Medical, which was acquired by Boston Scientific in 2018.
She is currently at Y Combinator as Group Partner where she invests
in and works closely with companies in the bio, healthcare, and
tech spaces. Surbhi is an invited speaker at universities including
Stanford and Harvard and has received numerous awards, including
named on the Forbes “30 under 30” list in 2014, the Inc “Female
Founders 100” list in 2019, Business Insider’s “Top Pioneering
Biotech VCs” list in 2022 and the Medical Device and Diagnostic
Industry “Omed 30 Under 30 Innovator” list in 2016. She currently
serves on boards for companies including Penumbra (NYSE: PEN) and
Astia, an angel group and venture fund that invests in female
entrepreneurs.
About Omniscient NeurotechnologyOmniscient
Neurotechnology (o8t™) builds personalized brain maps to diagnose,
treat and prevent health conditions. It operates on the core belief
that a better understanding of an individual’s brain will lead to
better outcomes for billions of people. Omniscient is a pioneer in
connectomics, the study of the brain's connections, and is poised
to change the future of neuroscience. Already used by neurosurgeons
to visualize the brain’s pathways prior to a procedure, the
company’s technology ultimately aims to transform brain health and
address conditions such as Alzheimer’s disease and depression.
Headquartered in Sydney, Australia with offices throughout the
world, Omniscient’s team consists of leaders in neurology, data
science and big tech. To learn more, visit o8t.com.
Media Contact:Kyle Owensmedia@o8t.com+1 (908)
947-0500 x709
GSI Technology (NASDAQ:GSIT)
Historical Stock Chart
From Jun 2024 to Jul 2024
GSI Technology (NASDAQ:GSIT)
Historical Stock Chart
From Jul 2023 to Jul 2024